Page last updated: 2024-11-04

gatifloxacin and Cholangitis, Sclerosing

gatifloxacin has been researched along with Cholangitis, Sclerosing in 1 studies

Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.

Cholangitis, Sclerosing: Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Happe, MR1
Mulhall, BP1
Maydonovitch, CL1
Holtzmuller, KC1

Other Studies

1 other study available for gatifloxacin and Cholangitis, Sclerosing

ArticleYear
Gatifloxacin-induced hyperglycemia.
    Annals of internal medicine, 2004, Dec-21, Volume: 141, Issue:12

    Topics: Anti-Infective Agents; Cholangitis, Sclerosing; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemi

2004